Brazil Launches Pilot Dengue Vaccinations With Single‑Dose Butantan Vaccine

Overview

• The Health Ministry began citywide vaccination of residents aged 15 to 59 in Botucatu, Maranguape and Nova Lima using the Butantan‑DV single‑dose vaccine.
• Authorities allocated 204,100 doses in this first stage, including 80,000 for Botucatu, to reach sufficient coverage for real‑world evaluation.
• Officials aim for roughly 40% to 50% coverage in each pilot city to assess population‑level effects on dengue transmission.
• Butantan‑DV is the first single‑dose dengue vaccine, authorized by Anvisa for ages 12 to 59, with trials showing about 74% overall efficacy, over 91% against severe disease and 100% protection from hospitalization.
• About 1.1 million primary‑care professionals are slated to start receiving shots on Feb. 9 if an additional 1.1 million doses arrive by Jan. 31, as production scales through a WuXi technology‑transfer that is expected to yield 25 to 30 million doses in 2026, while QDenga remains available to ages 10 to 14.